Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Cardiff Oncology Inc (CRDF)

Cardiff Oncology Inc (CRDF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 182,947
  • Shares Outstanding, K 66,526
  • Annual Sales, $ 680 K
  • Annual Income, $ -45,430 K
  • EBIT $ -52 M
  • EBITDA $ -52 M
  • 60-Month Beta 1.81
  • Price/Sales 260.07
  • Price/Cash Flow N/A
  • Price/Book 2.51

Options Overview Details

View History
  • Implied Volatility 168.27% ( +25.44%)
  • Historical Volatility 71.54%
  • IV Percentile 59%
  • IV Rank 23.25%
  • IV High 628.39% on 09/18/24
  • IV Low 28.90% on 05/22/24
  • Put/Call Vol Ratio 0.31
  • Today's Volume 384
  • Volume Avg (30-Day) 660
  • Put/Call OI Ratio 0.13
  • Today's Open Interest 36,264
  • Open Int (30-Day) 33,033

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate -0.20
  • Number of Estimates 4
  • High Estimate -0.18
  • Low Estimate -0.22
  • Prior Year -0.26
  • Growth Rate Est. (year over year) +23.08%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.42 +16.12%
on 05/07/25
3.28 -14.33%
on 04/23/25
unch (unch)
since 04/16/25
3-Month
2.36 +19.07%
on 04/11/25
4.99 -43.69%
on 02/21/25
-1.48 (-34.50%)
since 02/14/25
52-Week
2.01 +39.80%
on 08/05/24
5.64 -50.17%
on 12/17/24
-0.93 (-24.87%)
since 05/16/24

Most Recent Stories

More News
Cardiff Oncology: Q1 Earnings Snapshot

Cardiff Oncology: Q1 Earnings Snapshot

CRDF : 2.81 (+2.18%)
Cardiff Oncology Reports First Quarter 2025 Results and Provides Business Update

CRDF : 2.81 (+2.18%)
Cardiff Oncology Announces a Second Patent for the Treatment of mCRC for Bev-Naïve Patients

CRDF : 2.81 (+2.18%)
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CRDF : 2.81 (+2.18%)
Cardiff Oncology Announces Completion of Enrollment in Phase 2 CRDF-004 Trial Evaluating Onvansertib for the Treatment of First-line RAS-mutated Metastatic Colorectal Cancer

CRDF : 2.81 (+2.18%)
Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge

/CNW/ -- As the global cancer crisis intensifies, the demand for breakthrough treatments is reaching new heights. Statista data projects a 20% rise in annual...

ONCY : 0.4676 (-6.54%)
EXEL : 45.40 (-1.86%)
ONC.TO : 0.65 (-5.80%)
ALXO : 0.4374 (+0.37%)
CRDF : 2.81 (+2.18%)
VSTM : 7.59 (-4.29%)
Cardiff Oncology Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

CRDF : 2.81 (+2.18%)
Cardiff Oncology to Present at Upcoming Investor Conferences

CRDF : 2.81 (+2.18%)
Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update

CRDF : 2.81 (+2.18%)
Achievements and Progress Heading into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:GSK),(NASDAQ:AZN),(NYSE:ABBV),(NASDAQ:CRDF) EQNX::TICKER_END

ONCY : 0.4676 (-6.54%)
AZN : 68.81 (+1.25%)
ABBV : 184.02 (+1.29%)
ONC.TO : 0.65 (-5.80%)
GSK : 37.64 (+0.19%)
CRDF : 2.81 (+2.18%)

Business Summary

Cardiff Oncology Inc. is a clinical-stage biotechnology company. It engages in developing treatment for cancer patients. The company's product pipeline consists of a Phase 1b/2 study of onvansertib in combination with FOLFIRI/Avastin(R) in KRAS-mutated metastatic colorectal cancer; a Phase 2 study of...

See More

Key Turning Points

3rd Resistance Point 2.94
2nd Resistance Point 2.89
1st Resistance Point 2.85
Last Price 2.81
1st Support Level 2.75
2nd Support Level 2.70
3rd Support Level 2.66

See More

52-Week High 5.64
Fibonacci 61.8% 4.25
Fibonacci 50% 3.82
Fibonacci 38.2% 3.40
Last Price 2.81
52-Week Low 2.01

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar